サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1644055

ファーマ4.0の世界市場

Pharma 4.0

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ファーマ4.0の世界市場
出版日: 2025年01月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ファーマ4.0の世界市場は2030年までに403億米ドルに達する見込み

2024年に137億米ドルと推定されるファーマ4.0の世界市場は、2024年から2030年にかけてCAGR 19.7％で成長し、2030年には403億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるファーマ4.0ソフトウェアは、CAGR 17.8%を記録し、分析期間終了時には219億米ドルに達すると予測されます。ファーマ4.0サービス分野の成長率は、分析期間中CAGR 22.3%と推定されます。

米国市場は36億米ドル、中国はCAGR 18.7％で成長すると予測

米国のファーマ4.0市場は、2024年に36億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに62億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは18.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、それぞれ分析期間中に17.8%と17.3%のCAGRで成長すると予測されています。欧州では、ドイツがCAGR約14.7%で成長すると予測されています。

世界のファーマ4.0市場動向と促進要因まとめ

ファーマ4.0とは何か、製薬業界にどのような革命をもたらしているのか？

ファーマ4.0は製薬業界のパラダイムシフトを象徴し、人工知能（AI）、機械学習（ML）、モノのインターネット（IoT）、ブロックチェーンなどの先進技術を活用して、接続されたインテリジェントで自動化されたエコシステムを構築します。インダストリー4.0の原則に根ざしたファーマ4.0は、医薬品の製造とオペレーションを近代化し、効率性、コンプライアンス、品質管理を強化することを目指しています。このフレームワークは、スマートマニュファクチャリング、デジタル化されたサプライチェーン、予測分析を統合し、生産プロセスにおけるリアルタイムの意思決定と俊敏性の向上を可能にします。ファーマ4.0はまた、患者一人ひとりのニーズに合わせた正確で効率的な医薬品製造を可能にする、個別化医療のニーズの高まりにも対応しています。世界のヘルスケアシステムが、費用対効果の高いソリューションと新薬の市場投入までの時間短縮に対する要求の高まりに直面する中、ファーマ4.0は医薬品分野におけるイノベーションの礎となりつつあります。

技術の進歩はどのようにファーマ4.0の採用を形成していますか？

ファーマ4.0の採用は、実現技術の進歩によって大幅に加速しています。AIとMLが最前線にあり、製造装置の予知保全を推進し、生産スケジュールを最適化し、潜在的な品質問題が深刻化する前に特定します。IoTとセンサー技術は、生産環境のリアルタイムモニタリングを可能にし、温度や湿度などの変数を正確に制御します。ブロックチェーン技術は、サプライチェーンの透明性と安全性を高め、原材料からエンドユーザーまでの医薬品のトレーサビリティを可能にします。クラウドコンピューティングとデータ分析プラットフォームは、大量のデータのシームレスな統合と分析を容易にし、製薬会社がデータ主導の意思決定を行えるようにします。さらに、デジタルツイン（物理的プロセスの仮想レプリカ）は、実際の生産を中断することなく製造システムのテストと最適化を可能にし、ダウンタイムとコストを削減します。

ファーマ4.0の導入を促進している業界や利害関係者は？

ファーマ4.0の採用は、製薬メーカー、開発・製造受託機関（CDMO）、規制機関が主導しています。メーカー各社は、設備の近代化、無駄の削減、生産性の向上のためにこれらのテクノロジーを活用しています。医薬品製造のアウトソーシングにおいて重要な役割を果たすCDMOは、効率的でコンプライアンスに準拠したプロセスを求めるクライアントの要求に応えるため、ファーマ4.0ソリューションを統合しています。FDAやEMAなどの規制機関は、コンプライアンスとトレーサビリティを向上させるためにデジタル技術の採用を奨励しています。さらに、個別化医療や生物製剤の推進により、ファーマ4.0が可能にする柔軟な製造システムへの需要が急増しています。主なアプリケーションには、プロセスの自動化、リアルタイムの品質保証、予知保全などがあります。医薬品の複雑化とエンドツーエンドのトレーサビリティの必要性が、バリューチェーン全体におけるファーマ4.0ソリューションの採用をさらに促進しています。

ファーマ4.0市場の成長を促進する主な要因は？

ファーマ4.0市場の成長は、テクノロジーの進歩、規制枠組みの進化、業界ニーズの変化など、いくつかの要因によって促進されます。個別化された精密な医薬品に対する需要の高まりにより、製薬会社はファーマ4.0を利用した柔軟で自動化された製造システムを採用するようになりました。トレーサビリティとコンプライアンスに対する規制要件の高まりは、企業にブロックチェーンとIoTソリューションの統合を迫っています。さらに、複雑な生物製剤やバイオシミラーの普及に伴い、高度な品質管理対策が必要となっており、これはAI主導のアナリティクスによって実現可能です。データ主導の意思決定へのシフトは、クラウドコンピューティングやエッジコンピューティングの採用の高まりと相まって、市場の成長をさらに加速させています。さらに、医薬品製造における持続可能性とエネルギー効率の推進が、スマートで資源最適化された生産システムの需要を促進しています。テクノロジープロバイダーと製薬企業との協業が進み、デジタルトランスフォーメーションへの投資が増加していることが、ファーマ4.0市場の着実な成長を確実なものにしています。

セグメント

コンポーネント（ファーマ4.0ソフトウェア、ファーマ4.0サービス）、テクノロジー（人工知能・機械学習テクノロジー、ビッグデータ分析テクノロジー、IoTテクノロジー、ブロックチェーンテクノロジー、その他テクノロジー）、用途（創薬・開発用途、製造用途、サプライチェーンマネジメント用途、その他用途）、最終用途（製薬・バイオ企業最終用途、CRO・CDMO最終用途、ヘルスケアプロバイダー最終用途）

調査対象企業の例（注目の25社）

  • Amazon Web Services, Inc.
  • Aspen Technology, Inc.
  • Cisco Systems, Inc.
  • GE Healthcare
  • IBM Corporation
  • Lighthouse Worldwide Solutions Inc.
  • nexocode
  • Oracle Corporation
  • Tulip Interfaces, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32549

Global Pharma 4.0 Market to Reach US$40.3 Billion by 2030

The global market for Pharma 4.0 estimated at US$13.7 Billion in the year 2024, is expected to reach US$40.3 Billion by 2030, growing at a CAGR of 19.7% over the analysis period 2024-2030. Pharma 4.0 Software, one of the segments analyzed in the report, is expected to record a 17.8% CAGR and reach US$21.9 Billion by the end of the analysis period. Growth in the Pharma 4.0 Services segment is estimated at 22.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 18.7% CAGR

The Pharma 4.0 market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.2 Billion by the year 2030 trailing a CAGR of 18.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.8% and 17.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.7% CAGR.

Global Pharma 4.0 Market - Key Trends & Drivers Summarized

What Is Pharma 4.0 and How Is It Revolutionizing the Pharmaceutical Industry?

Pharma 4.0 represents a paradigm shift in the pharmaceutical industry, leveraging advanced technologies such as artificial intelligence (AI), machine learning (ML), Internet of Things (IoT), and blockchain to create a connected, intelligent, and automated ecosystem. Rooted in the principles of Industry 4.0, Pharma 4.0 aims to modernize pharmaceutical manufacturing and operations, ensuring enhanced efficiency, compliance, and quality control. The framework integrates smart manufacturing, digitalized supply chains, and predictive analytics to enable real-time decision-making and greater agility in production processes. Pharma 4.0 also addresses the growing need for personalized medicine, enabling precise and efficient drug production tailored to individual patient needs. As global healthcare systems face increasing demands for cost-effective solutions and faster time-to-market for new drugs, Pharma 4.0 is rapidly becoming the cornerstone of innovation in the pharmaceutical sector.

How Are Technological Advancements Shaping the Adoption of Pharma 4.0?

The adoption of Pharma 4.0 has been significantly accelerated by advancements in enabling technologies. AI and ML are at the forefront, driving predictive maintenance in manufacturing equipment, optimizing production schedules, and identifying potential quality issues before they escalate. IoT and sensor technologies enable real-time monitoring of production environments, ensuring precise control over variables such as temperature and humidity. Blockchain technology enhances supply chain transparency and security, enabling traceability of pharmaceutical products from raw materials to end-users. Cloud computing and data analytics platforms facilitate seamless integration and analysis of large volumes of data, empowering pharmaceutical companies to make data-driven decisions. Furthermore, digital twins—virtual replicas of physical processes—allow for testing and optimization of manufacturing systems without disrupting actual production, thereby reducing downtime and costs.

Which Industries and Stakeholders Are Driving the Adoption of Pharma 4.0?

Pharma 4.0 adoption is being led by pharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and regulatory bodies. Manufacturers are leveraging these technologies to modernize facilities, reduce waste, and enhance productivity. CDMOs, which play a critical role in outsourced drug production, are integrating Pharma 4.0 solutions to meet client demands for efficient and compliant processes. Regulatory bodies such as the FDA and EMA are encouraging the adoption of digital technologies to improve compliance and traceability. In addition, the push for personalized medicine and biologics has created a surge in demand for flexible manufacturing systems that Pharma 4.0 enables. Key applications include process automation, real-time quality assurance, and predictive maintenance. The increasing complexity of pharmaceutical products and the need for end-to-end traceability are further driving the adoption of Pharma 4.0 solutions across the value chain.

What Are the Key Drivers Fueling the Growth of the Pharma 4.0 Market?

The growth in the Pharma 4.0 market is driven by several factors, including advancements in technology, evolving regulatory frameworks, and changing industry needs. The rising demand for personalized and precision medicines has prompted pharmaceutical companies to adopt flexible and automated manufacturing systems enabled by Pharma 4.0. Increasing regulatory requirements for traceability and compliance are compelling firms to integrate blockchain and IoT solutions. Additionally, the growing prevalence of complex biologics and biosimilars necessitates advanced quality control measures, which are achievable through AI-driven analytics. The shift toward data-driven decision-making, coupled with the rising adoption of cloud and edge computing, has further accelerated market growth. Furthermore, the push for sustainability and energy efficiency in pharmaceutical manufacturing is driving demand for smart, resource-optimized production systems. The increasing collaboration between technology providers and pharmaceutical companies, along with rising investments in digital transformation, is ensuring steady growth in the Pharma 4.0 market.

SCOPE OF STUDY:

The report analyzes the Pharma 4.0 market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Pharma 4.0 Software, Pharma 4.0 Services); Technology (Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology, Other Technologies); Application (Drug Discovery & Development Application, Manufacturing Application, Supply Chain Management Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, CRO & CDMO End-Use, Healthcare Providers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 25 Featured) -

  • Amazon Web Services, Inc.
  • Aspen Technology, Inc.
  • Cisco Systems, Inc.
  • GE Healthcare
  • IBM Corporation
  • Lighthouse Worldwide Solutions Inc.
  • nexocode
  • Oracle Corporation
  • Tulip Interfaces, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Economic Frontiers: Trends, Trials & Transformations
    • Pharma 4.0 - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Adoption of Smart Manufacturing Systems in Pharmaceuticals Propels Growth
    • Increasing Use of IoT for Real-Time Monitoring Drives Pharma 4.0 Adoption
    • AI and Machine Learning Enable Predictive Quality Control, Fueling Demand
    • Expansion of Continuous Manufacturing Processes Enhances Market Potential
    • Integration of Blockchain in Pharma Supply Chains Boosts Market Growth
    • Digital Twins for Drug Development Propel Pharma 4.0 Deployment
    • Advancements in Robotics Drive Efficiency in Pharmaceutical Manufacturing
    • Rising Demand for Personalized Medicine Fuels Adoption of Pharma 4.0 Technologies
    • Increased Focus on Data Analytics Improves Decision-Making in Pharma Operations
    • Expansion of Cloud-Based Pharma Solutions Drives Market Growth
    • AR and VR Technologies Revolutionize Pharma Training and Operations
    • Predictive Maintenance Enhances Equipment Management Efficiency
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pharma 4.0 Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pharma 4.0 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Pharma 4.0 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Pharma 4.0 Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Pharma 4.0 Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Pharma 4.0 Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Pharma 4.0 Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Supply Chain Management Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Supply Chain Management Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Manufacturing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Manufacturing Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for CRO & CDMO End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for CRO & CDMO End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Healthcare Providers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Healthcare Providers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Artificial Intelligence & Machine Learning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Artificial Intelligence & Machine Learning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Big Data Analytics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Big Data Analytics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for IoT Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for IoT Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Blockchain Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Blockchain Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • JAPAN
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • CHINA
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • EUROPE
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Pharma 4.0 by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • FRANCE
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • GERMANY
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • ITALY
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030

IV. COMPETITION